Eric Fader, Jeff Kaiser, Chris Kutner, Ada Kozicz and Ben Malerba are authors of the newly released book, “The Federal Anti-Kickback Statute and Safe Harbors: A Practical Guide.”

Published by the American Bar Association, the book covers all safe harbors currently in place, as well as the interplay between the Anti-Kickback Statute (AKS) and other

Marc Ullman spoke with Vitamin Retailer about the repercussions of the Coronavirus pandemic on the natural products industry. He was joined by 11 other panelists representing manufacturers, industry associations and consultants to the industry.

To read the Q&A click here.

Marc Ullman was cited in Nutritional Outlook’s article, “High anxiety: Will CBD ever be legal in foods and beverages?”

The article discusses whether or not the FDA will ever approve the use of CBD in foods and beverages. Currently, it is not a lawful ingredient. Ullman provided advice on the procedures necessary to prove the

Marc Ullman was quoted in a Nutraingredients-USA.com article entitled “Warning letter cites CBD’s regulatory status as leading issue.”

The Food and Drug Administration sent a warning letter to a supplement manufacturer regarding various failures in good manufacturing practice (GMP). For the first time, however, the letter cited the health claims made about CBD as the first

Marc Ullman was quoted in the Nutraingredients-USA.com article, “NPA calls for FDA to issue import alerts on imported adulterated dietary supplement ingredients.”

The Natural Products Association is requesting that the Food and Drug Administration deal with the import of nutritional supplements that fail to comply with New Dietary Ingredient (NDI) regulations. Marc noted that FDA has

Robert Iseman spoke to Part B News about how medical practices should take steps to protect themselves from legal and insurance issues.

The article, “Assess legal risk, payer policies to head off hidden dangers of COVID-19 reopening,” advises medical practices that are beginning to reopen on preparations they can make to be ready for any

Marc Ullman was quoted in the Nutraingredients-usa.com article, “CRN ends NAD funding, but value of claims evaluation program will go on.”

Click here to read the article.

On April 16, 2020, Michael Troisi will be a faculty member for the webinar, “COVID-19 and Business Interruption Coverage: Policyholder and Insurer Perspective.”

Sponsored by the Torts, Insurance, & Compensation Law Section of the New York State Bar Association, the webinar will explore coverage dilemmas and discussions addressing unique policy positions and arguments from both

On April 6, Rivkin Radler’s Eric Fader presented a COVID-19 Business Briefing on Telehealth. The Briefing covered recent developments in federal and state law and policy, and changes in private insurers’ policies, that have been aimed at encouraging the use of telehealth during the current public health emergency.

This Business Briefing was the second in

Marc Ullman spoke with NutraingredientsUSA.com about the impact of the ABH recall on the entire nutritional supplements industry, as thousands of products were recalled as part of a consent decree, which covered 859 businesses and brands. ABH is a contract manufacturer that was sanctioned by the FDA for repeatedly failing to comply with regulations.

Marc